Ideas, science and stories.

Clinical studies

Inside SiPore®'s clinical program — from in vitro and in vivo work to the randomised, placebo-controlled SHINE trial.

Publications

Peer-reviewed science behind SiPore® — nine publications across preclinical and clinical research, including the SHINE trial published in eClinicalMedicine, within of The Lancet Discovery Science portfolio.

Mechanism research

The science behind enzyme entrapment — how engineered porous silica slows digestion at the source, step by step.

Safety & tolerability

Why SiPore® is designed to be gentle — pure silica, non-systemic action, and a demonstrated safety profile in the SHINE trial.

A Clinical Strategy for Integrating SiPore® Throughout the Metabolic Peptide Journey

How are practitioners thinking about SiPore® alongside GLP-1 and other metabolic peptides? Alexis Gonzalez discusses the questions that arise at different stages of the patient journey, from starting use to considering a transition away.

SiPore® Practitioner Portfolio Now Available on Fullscript, Expanding Access to Gut-Local Metabolic Health Solutions Across the United States

Healthcare practitioners can now recommend SiPore® Capsules and SiPore® Liquid directly through Fullscript to support earlier, meal-focused metabolic care

Sigrid Therapeutics Launches on Fullscript, Expanding U.S. Practitioner Access

Partnership provides access to more than 125,000 healthcare providers across North America, accelerating the commercial expansion of Sigrid's patented SiPore® technology platform

Sigrid Therapeutics Announces Publication of the SHINE Clinical Trial in The Lancet's eClinicalMedicine

Sigrid Therapeutics today announced the publication of the SHINE clinical trial in eClinicalMedicine, part of The Lancet Discovery Science portfolio. The publication marks a major scientific…

The SHINE Trial

Explore the latest major randomized, placebo-controlled clinical research evaluating SiPore®.

SIGRID Therapeutics Launches Carb Fence™, a New Gut-Local Approach Designed to Reduce the Negative Impact of Modern Meals

SIGRID Therapeutics launches Carb Fence™, a new gut-local medical food designed to reduce the negative impact of modern meals. Powered by patented SiPore® technology, Carb Fence™ helps support…

SIGRID Therapeutics Launches Carb Fence™, Its Flagship Gut-Local Medical Food, in the United States

SIGRID Therapeutics announces the U.S. launch of Carb Fence™, its flagship medical food powered by patented SiPore® technology. The launch brings the clinically evaluated 9 g daily SiPore® dose to…

How SiPore® Works (Step by Step)

What Is Metabolically Healthy?

Post highlights: -What “metabolically healthy” really means -Why metabolic health affects energy, appetite, and long-term wellbeing -How modern meals can place stress on metabolism -Signs of…

Modern Food Systems Set Us Up for Failure

Sigrid Therapeutics appoints Claus Kjærsgaard as Chief Executive Officer

Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovative solutions for metabolic health, today announced the appointment of Claus Kjaersgaard as its new Chief…

Sigrid Enters Exclusive Global Licensing and Research Collaboration to Commercialize SiPore® in Consumer Oral Health

Sigrid today announced that it has entered into an exclusive global licensing and research collaboration with a leading multinational consumer health company to expand the SiPore® technology…

Sigrid raises SEK 45 million to scale up its groundbreaking technology for metabolic health

Sigrid, a Swedish innovation company in consumer health, today announces that the company has raised SEK 45 million in new capital.

Johannes Cullberg Podcast

The fight against obesity and type 2 diabetes with Prof. Tore Bengtsson

I tried the alternative to the fat jab — did I lose weight?

First it was the Danes with Wegovy. Now Swedish scientists have come up with a solution to the obesity epidemic: SiPore®. Michael Odell tries drinking it.

How the new 'liquid Ozempic' helped me to scoff mt way through Christmas for 3 weeks and STILL lose weight

Katie Glass recalls her struggles with gaining weight and the failure to overcome it from lacklustre current measures before trying Sigrid’s Glucose Stabiliser.

Forbes explores the story behind SiPore®

Forbes contributor Geri Stengel explores the founders’ story, the research behind SiPore® and the entrepreneurial journey of Sigrid Therapeutics.

Sigrid Therapeutics aims to ward off Type 2 diabetes with an edible, powdered medical device

Conor Hale identifies SiPore® innovative mode of action, an oversubscribed funding round and Sigrid Therapeutic’s promising path ahead.